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Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent 
life- threatening, hereditary disease. ADPKD is more common than sickle cell anemia, cystic 
ﬁ  brosis, muscular dystrophy, hemophilia, Down’s syndrome, and Huntington’s disease com-
bined. ADPKD is a multisystemic disorder characterized by the progressive development of 
renal cysts and marked renal enlargement. Structural and functional renal deterioration occurs 
in ADPKD patients and is the fourth leading cause of end-stage renal disease (ESRD) in adults. 
Aside from the renal manifestations, extrarenal structural abnormalities, such as liver cysts, 
cardiovascular abnormalities, and intracranial aneurysms may lead to morbidity and mortality. 
Recent studies have identiﬁ  ed prognostic factors for progressive renal impairment including 
gender, race, age, proteinuria, hematuria, hypertension and increased left ventricular mass 
index (LVMI). Early diagnosis and better understanding of the pathophysiology of the disease 
provides the opportunity to aggressivly treat hypertension with renin-angiotensin-aldosterone 
system inhibitors and thereby potentially reduce LVMI, prevent cardiovascular morbidity and 
mortality and slow progression of the renal disease.
Keywords: hypertension, liver cysts, renal pain, left ventricular hypertrophy, cerebral 
aneurysms
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by renal 
cyst enlargement, resulting in abnormal kidney structure and renal insufﬁ  ciency. End 
stage renal disease (ESRD) will be observed in 50% of cases by the ﬁ  fth decade. 
ADPKD is the most common life- threatening, hereditary disease, which affects 1:400 
to 1:1000 live births (Ecder et al 2006). The incidence of ADPKD is more frequent 
than sickle cell anemia, cystic ﬁ  brosis, muscular dystrophy, hemophilia, Down’s 
syndrome, and Huntington’s disease combined (PKD Foundation 2000). ADPKD is 
genetically heterogeneous with separate loci on chromosome 16 (PKD1), accounting 
for approximately 85% of ADPKD cases, and on chromosome 4 (PKD2), accounting 
for approximately 15% of patients (Kimberling et al 1993).
Numerous renal and extra-renal manifestations have been described for ADPKD. 
Hypertension, left ventricular hypertrophy, cardiac valvular defects, back and abdominal 
pain, cerebral aneurysms, and liver cysts are the most important clinical ﬁ  ndings. There 
are several risk factors, which affect the progression of renal disease such as gender, 
race, age, renal volume, hypertension, proteinuria and hematuria (Gabow et al 1992). It 
has been shown that the disease is more severe in PKD1 patients as compared to PKD2. 
Hypertension and proteinuria are more pronounced in PKD1 patients (Chapman et al 
2003; Grantham et al 2006a). In both PKD1 and PKD2, older patients generally have 
more cysts, indicating that the cystogenesis continues throughout the life of patients. 
Renal volume is highly associated with hypertension and both have signiﬁ  cant impact 
on renal outcomes (Fick-Brosnahan et al 2002; Schrier et al 2003). Recently it has Therapeutics and Clinical Risk Management 2008:4(2) 394
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been deﬁ  ned that the rate of cyst growth is comparable in 
PKD1 and PKD2. However, the number of cysts is greater 
in PKD1 patients (Harris et al 2006). Male, as compared to 
female, patients of European descent tend to have more severe 
disease with faster expansion of cyst volumes. There are some 
preliminary results indicating that African-Americans exhibit 
worse disease than ADPKD patients of European descent 
(Gabow et al 1992). Understanding the natural history of 
the disease, clinical risk factors and targeting the treatable 
aspects of the disease are the main foci in order to choose the 
appropriate interventions.
Diagnosis
The diagnosis of ADPKD is usually made by family history 
and renal imaging. In the case of affected family members 
gene linkage analysis has been used. However, genetic 
studies are expensive but may be employed if the diagnosis 
is uncertain and renal imaging is not informative. A recent 
study showed that physicians and patients’ awareness of 
the hereditary basis of ADPKD has led to better family 
histories and an earlier diagnosis of ADPKD (Taylor et al 
2005). Earlier diagnosis could have beneﬁ  cial effects with 
interventions to slow renal disease progression and prevent 
cardiovascular complications in ADPKD patients. In recent 
years, with the widespread availability of ultrasonography, 
this modality has been established as the main radiologic 
technique for diagnosis of ADPKD (Elles et al 1994; Gabow 
et al 1997). In one study ultrasonograghy was found to be 
more reliable in patients older than 30 years and especially 
in PKD1 (Nicolau et al 1999). Diagnostic criteria based on 
US ﬁ  ndings in individuals with positive family history are 
shown in Table 1.
In 2002, Fick et al demonstrated that total kidney vol-
ume and renal cyst volumes were strongly correlated with 
the decline of glomerular ﬁ  ltration rate (GFR) (Figure1) 
(Fick-Brosnahan et al 2002; Chapman et al 2003). A recent 
national study conducted by the Consortium of Radiologic 
Imaging Studies of Polycystic Kidney Disease (CRISP) 
provides support for this view (Grantham et al 2006b). They 
have shown that cystic growth rate is highly variable among 
ADPKD patients but it is mostly a progressive process during 
the course of the disease. Patients with larger kidneys have 
the fastest rates of renal volume enlargement (Grantham et al 
2006b). Thus, measurement of renal volume is of clinical rel-
evance. Although ultrasonography is safe, easily performed, 
available and inexpensive, it is not precise enough to detect 
short-term disease progression (O’Neill et al 2005). Magnetic 
resonance imaging (MRI) has been shown to be more sensi-
tive and reliable for measurement of the renal cyst volume. 
In contrast to ultrasonograghy, MRI is being evaluated as a 
useful technique to determine the cystic changes over a short 
time period (Chapman et al 2003).
Hypertension
Hypertension is the most frequent complication among 
ADPKD patients, occurring in approximately 60% of the 
patients, while their glomelural ﬁ  ltration rate (GFR) is still 
in the normal range (GFR   75 mL/min/1.73 m2) (Gabow, 
Chapman et al 1990; Chapman et al 1991). Compared to the 
general population hypertension occurs at a much earlier 
age in ADPKD patients (Kelleher et al 2004). The median 
age at hypertension diagnosis in ADPKD was found to be 
32 years for males and 34 years for females (Figures 2a and 
2b). The occurrence of hypertension is greater in both male 
and female ADPKD patients when their affected parents are 
hypertensive. Moreover, the age of diagnosis of hypertension 
is also earlier in ADPKD patients with affected hypertensive 
parents (Schrier et al 2003). Several studies have shown that 
hypertension in ADPKD patients is associated with increased 
renal volumes and left ventricular mass index (LVMI), in 
both adults and children (Sedman et al 1987; Chapman et al 
1997; Gabow et al 2006a). Hypertension and LVMI are 
important risk factors for cardiovascular disease, which is 
the most common cause of death in patients with ADPKD 
(Fick et al 1995).
Angiographic studies have demonstrated that cyst 
enlargement in ADPKD is associated with compression of 
the adjacent parenchyma and vasculature, with resultant 
areas of renal ischemia (Ettinger et al 1969). Several studies 
have shown elevated concentrations of renin in both tissue 
and cyst ﬂ  uid from ADPKD patients (Torres et al 1992). 
Further studies have indicated an intrarenal role of RAAS 
by detecting the angiotensinogen, angiotensin-converting 
enzyme (ACE), angiotensin II type 1 (AT1) receptor, and 
angiotensin II within cysts and tubules of ADPKD kidneys 
(Loghman-Adham et al 2004). These results support 
activation of the renin-angiotensin-aldosterone system 
(RAAS) secondary to renal ischemia. The ﬁ  rst clue of 
RAAS activation in ADPKD arose from clinical studies, 
Table 1 Criteria for diagnosing autosomal dominant polycystic 
kidney disease (ADPKD) by renal ultrasound
Age (years)  Criteria
 30  At least 2 renal cysts (Unilateral or Bilateral)
30–59  At least 2 cysts in each kidney
 60  At least 4 cysts in each kidneyTherapeutics and Clinical Risk Management 2008:4(2) 395
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which demonstrated an increase in the plasma renin activity 
(PRA) with captopril, an ACE inhibitor, in hypertensive, 
but not normotensive patients with ADPKD (Anderson et al 
1979; Torres et al 1991). Since an increase in blood pressure 
may decrease PRA, a comparison of the RAAS in patients 
with essential hypertension and hypertensive ADPKD 
patients who were matched was undertaken at comparable 
blood pressure (BP), renal function, age, and sodium 
intake. These studies demonstrated signiﬁ  cantly higher 
PRA and plasma aldosterone concentrations in the supine 
and upright positions, as well as after ACE inhibition, with 
captopril in the ADPKD patients as compared to essential 
hypertension patients. In addition, after six weeks of ACE 
inhibition with enalapril, ADPKD hypertensive patients 
exhibited a signiﬁ  cant increase in renal plasma ﬂ  ow due 
to decrease in renal vascular resistance and consequently 
a decrease in ﬁ  ltration fraction rate as compared to essential 
hypertension patients (Watson et al 1992; Ecder et al 
2001). In a retrospective study, ADPKD hypertensive 
patients received either ACE inhibitor or diuretics. During 
a mean follow-up of 5 years, patients who were treated 
with diuretics without any ACE inhibitors had a greater 
decrease in GFR and an increase in serum creatinine 
levels compared with patients who were taking only ACE 
inhibitors. Although systolic or diastolic blood pressure at 
baseline or at the end of the survey showed no differences, 
the diuretic group needed more additional antihypertensive 
drugs for comparable blood pressure control than the ACE 
inhibition group (64 vs 21%, p   0.05) (Ecder et al 2001). 
In an epidemiological paper, it was shown that the risk for 
male ADPKD male patients entering end stage renal disease 
(ESRD) is 10 times higher among those with a mean arterial 
Figure 1 Correlation between GFR and renal volume in ADPKD patients.Therapeutics and Clinical Risk Management 2008:4(2) 396
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pressure (MAP) greater than 93 mm Hg ( 120/80 mm Hg) 
compare to those patients with a MAP less than 93 mm Hg. A 
similar analysis estimated that female ADPKD patients with 
a MAP greater than 93 mm Hg were 2.4 times more likely to 
progress to ESRD than those patients with MAP of 93 mm Hg 
or less. Further, when ADPKD patients from 1985–1992 were 
compared with ADPKD patients from 1992–2001, a later 
age of ESRD onset was observed in the more recent group 
in which more aggressive control of hypertension has been 
emphasized (Figure 3) (Schrier et al 2003).
Left ventricular hypertrophy
As already noted, in the era of renal replacement therapy 
with dialysis or transplantation, cardiovascular disease is 
the leading cause of death in patients with ADPKD (Fick 
et al 1995). One important risk factor is left ventricular 
hypertrophy (LVH), which exacerbates cardiac morbidity 
and mortality in patients with other types of disease. 
Due to early onset of hypertension in ADPKD patients, 
a signiﬁ  cant correlation between LVH and mean arterial 
pressure may be seen (Figure 4). Left ventricular mass 
index (LVMI) is highly related to systolic blood pressure 
in ADPKD (Bardaji et al 1998). In 116 ADPKD patients in 
their early 40s, LVH was found in 46% of male and 37% 
in female patients. LVH has also been detected in 23% of 
ADPKD patients with normal blood pressure (Chapman 
et al 1997; Ecder et al 2001). This may be due to the 
observation that BP may not decrease at night in ADPKD 
patients, ie, non-dippers.
A prospective study demonstrated that ACE inhibition with 
enalapril controlled BP and reversed LVH in hypertensive 
ADPKD patients (Ecder et al 1999). A recent randomized 
Males
Figure 2 Prevalence of hypertension in autosomal dominant polycystic kidney disease () in (a) males and (b) females 1995–2000 vs NHANES IV ().Therapeutics and Clinical Risk Management 2008:4(2) 397
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prospective study on 75 hypertensive ADPKD patients with 
LVH demonstrated that rigorous BP control ( 120/80 mmHg) 
versus standard (135–140/85–90 mmHg) BP control over a 
7-year follow-up period had a signiﬁ  cantly greater reversal 
of LVH. Both standard and rigorous BP control groups had 
decreased LVH, but LVMI was returned to the normal range 
in more patients in the rigorous BP control group than in the 
standard BP group (71% vs. 44%) (Figure 5). Moreover, 
patients receiving the ACE inhibitor enalapril had a greater 
decrease in LVMI as compared to those who received 
amlodipine, a calcium channel blocker (Ecder at al 1999; 
Schrier et al 2002). Thus, the use of an ACE inhibitor and 
maintenance of a blood pressure goal at 120/80 mmHg in 
hypertensive ADPKD patients with LVH should be undertaken 
(Ecder and Schrier 2004). Another study was conducted among 
20 hypertensive ADPKD patients compared with an age-and 
sex-matched essential hypertensive subjects designated as a 
control group. Both groups had the same 24 hour ambulatory 
BP and LVMI, although male ADPKD patients had higher 
LVMI than their matched controls. LVH was detected in 
40% of ADPKD patients compared to 30% of the essential 
hypertensive group. ADPKD patients with LVH did not differ 
Figure 3 Survival Curves for end-stage renal failure (ESRD) in (a) male and (b) female ADPKD patients from 1985–1992 vs 1992–2001 (n = 97).Therapeutics and Clinical Risk Management 2008:4(2) 398
Masoumi et al
Figure 4 Correlation between blood pressure and left ventricular hypertrophy in ADPKD patients.
Figure 5 (a) Effect of rigorous ( ) versus standard (¡) blood pressure control to decrease left ventricular mass index in autosomal dominant polycystic kidney disease 
(ADPKD) patients. (b) Effect of blood pressure control with amlodipine (¡) versus enalapril ( ) to decrease left ventricular mass index in ADPKD patients.Therapeutics and Clinical Risk Management 2008:4(2) 399
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from those without LVH, except that they had higher 24-hour 
ambulatory BP levels. This study indicates a correlation 
between LVMI and 24-hour systolic and diastolic blood 
pressure in ADPKD patients (Martinez et al 2000). ADPKD 
patients may demonstrate insulin resistance (Hjelmesaeth 
and Hartmann 1999), thus studies have been conducted to 
determine the prevalence of LVH among these patients. 
Results showed a signiﬁ  cant association between LVMI and 
insulin resistance independently of other factors such as age, 
weight, systolic blood pressure and albuminuria (Lumiaho et al 
2003). The stimulation of angiotensin II (Rocchini et al 1990) 
and the sympathetic nervous system secondary to elevated 
insulin levels therefore may have a major role in increased 
LVMI in ADPKD patients (Lembo et al 1992).
In addition to LVH, valvular disorders are common among 
ADPKD patients. It has been shown that the prevalence of 
mitral valve prolapse (MVP) is higher in ADPKD patients as 
compared to general population (26% vs 2%). ADPKD patients 
also have an increased risk of tricuspid valve prolapse (6%). 
Mitral and aortic incompetence also has been detected more 
frequent in ADPKD patients (31 and 8 percent respectively) 
(Hossack et al 1988; Timio et al 1992; Martinez-Vea 1999).
ADPKD in children
ADPKD is usually considered an adult disease. In the 1970s 
and 1980s cases of early disease in children and even in utero 
were described (Blyth and Ockenden 1971; Kaye and Lewy 
1974; Bengtsson et al 1975; Garel et al 1983; Pretorius et al 
1987). Thus, modern imaging techniques, especially renal 
ultrasonograghy, emerged as the procedure to diagnose 
ADPKD. In one study approximately 60%–90% of PKD 
gene carriers under the age of 20 years were recognized by 
renal ultrasonograghy (Sedman et al 1987). Recently, it has 
been shown that the sensitivity of ultrasonograghy in ADPKD 
patients younger than 30 years is almost 95% (Nicolau et al 
1999). In a study on PKD-1 gene mutation carriers, among 
0–5-year-old children, renal cysts were detected in 60% of 
the study group by ultrasound. In children aged 5–18 years, 
75%–80% had detectable cysts by renal ultrasound (Gabow 
et al 1997). ADPKD children, in addition to their renal cysts, 
may present with a variety of clinical ﬁ  ndings, ranging 
from newborns with severe disease including massive renal 
enlargement, hypertension, oliguria, and pulmonary hypopla-
sia to the absence of signs or symptoms (Mcdonald et al 1999). 
Unlike adults, the factors in children, which have an impact 
on the disease progression, are not well understood (Fick et al 
1994). GFR is not a reliable predictor of disease progression 
in children (Fick et al 1993). Fick et al in an observational 
study on 312 children described the characteristics, which 
are associated with faster renal volume growth. Risk factors 
were renal enlargement in utero or the ﬁ  rst year of life, high 
blood pressure and the presence of more than 10 renal cysts 
before age 12 years. The rate of renal enlargement may be 
a relevant marker for disease progression. However, there 
is considerable variability in renal volumes among affected 
children. Nevertheless, at any given age, the affected children 
had signiﬁ  cantly larger kidneys as compared to non-affected 
children (Fick et al 2001).
Most ADPKD children have less than 10 cysts before 
12 years of age, but children with more than 10 cysts generally 
have more severe disease. The prevalence of high blood 
pressure and ﬂ  ank and/or back pain is higher in the children 
with more cysts and larger kidneys. Polyuria and impaired 
urinary concentration are also associated with larger kidneys 
(Fick et al 1994). Children with more than 10 cysts, compared 
to  children with less than 10 cysts, had a greater annual increase 
in renal volumes even though they were younger at their ﬁ  rst 
and last visits. Evaluating the number of renal cysts might be 
more practical in children than measuring age-adjusted renal 
volumes. Also children with higher blood pressure exhibited 
greater renal growth rate. In contrast to adults, in children 
gender distribution does not seem to have an impact on renal 
disease progression rate (Fick et al 2001).
In a recent ADPKD study in children, those cases 
with very early onset of disease (VEO) (ie, diagnosed 
before 18 months of life) and children diagnosed between 
18 months and 18 years of age (non-VEO) have been 
evaluated and compared. When adjusted for age, the VEO 
group had larger renal volumes, more frequent hypertension, 
and higher serum creatinine, lower creatinine clearance and 
estimated GFR compared with non-VEO children. LVMI 
was also greater in VEO children (Figure 6). Proteinuria, 
hematuria, and symptoms at diagnosis in both groups 
were correlated with signiﬁ  cantly larger age-adjusted renal 
volumes (Shamshirsaz et al 2005). Interestingly, over 90% of 
VEO children maintained preserved renal function well into 
childhood and in general their growth was normal (Sedman 
et al 1987; Taitz et al 1987; Fick et al 1993; Shamshirsaz 
et al 2005). However, because of the potential for severe 
complications such as hypertension and renal insufﬁ  ciency, 
these children should be closely and regularly monitored. 
Due to the signiﬁ  cant association between larger kidneys 
and early progression to ESRD, the beneﬁ  cial effects of 
reducing renal growth and LVMI by RAAS blockers was 
considered important. Such a prospective study is underway 
at the University of Colorado Health Sciences Center.Therapeutics and Clinical Risk Management 2008:4(2) 400
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Similar to the adult population with ADPKD, there 
is also a greater prevalence of MVP among the pediatric 
population (Ivy et al 1995). Leier at al (1984) reported that 
36% of ADPKD patients have bicuspid aortic valve, but 
the prevalence of congenital cardiac diseases in adults with 
ADPKD is unknown.
Proteinuria
The presence of proteinuria may be an indicator of sub-
clinical end-organ damage in addition to kidney damage, 
including the presence of LVH and systemic atherosclerosis. 
Recent studies have shown signiﬁ  cant association between 
LVMI and proteinuria (Leoncini, Viazzi et al 2002; Leoncini, 
Sacchi et al 2002; Pontremoli et al 2002). Microalbuminuria 
(30–300 mg/24 h in adults), a sensitive measure of urinary 
albumin excretion, has been useful in identifying the risk of 
developing diabetic nephropathy. It has also been positively 
related to an increased risk of cardiovascular mortality in 
essential hypertensive patients, especially old, obese, and male 
patients. In ADPKD patients, proteinuria is considered to be 
an important predictor of renal disease progression. In a study 
of 270 ADPKD patients only 18% of cases presented with 
established proteinuria ( 300 mg/day). Interestingly all these 
patients had hypertension and also had large renal volumes. 
Renal functional impairment was greater in these patients 
who also showed a faster tendency for disease progression and 
an increased incidence of hematuria (Chapman et al 1994). 
Furthermore, 41% of hypertensive ADPKD patients with LVH 
showed some degree of microalbuminuria (30–300 mg/24 h). 
These patients with microalbuminuria and LVH had higher 
MAP (MAP 107 vs 113, p   0.005) and renal volumes (535 vs 
853 cm3, p   0.01) (Ecder et al 2001). A 5-year prospective, 
randomized study of 24 ADPKD patients was conducted to 
examine the antialbuminuric effect of amlodipine, a calcium 
channel blocker, versus enalapril, an ACE inhibitor, on urinary 
albumin/creatinine ratio. Albumin to creatinine ratio increased 
signiﬁ  cantly in the amlodipine related patients, but was stable in 
the enalapril-treated ADPKD patients at comparable levels of 
BP control. (Ecder et al 2000) Thus, we can tentatively propose 
that the sustained antialbuminuric effect of ACE inhibitors may 
improve the long-term renal and cardiovascular prognosis in 
ADPKD patients.
Pain
The most frequent complaint in ADPKD patients is pain, 
occurring in approximately 60% of patients (Gabow 1990). 
Severe abdominal and ﬂ  ank pain is a known frustrating 
experience among ADPKD patients (Mulutinovic et al 1984; 
Mulutinovic et al 1990). In a recent study of 171 ADPKD 
patients, 71.3% reported lower back pain, which was the most 
common pain pattern in this group. 29.6% of this group had 
radiculopathy symptoms. Abdominal pain was seen in 61.4% 
of these patients. The abdominal pain was described as dull 
pain (49.5%), uncomfortable fullness (42.7%), stabbing pain 
(40.4%), and cramping (33.0%) (Bajwa et al 2004). This pain 
can occur both acutely or persist on a chronic basis.
Acute pain
Cyst rupture or hemorrhage, infected cysts and renal stones 
are considered as the most common etiologies of acute 
 
(
 
 
 
 
 
 
 
 
)
Figure 6 Renal volumes in age-adjusted VEO children and non-VEO children.Therapeutics and Clinical Risk Management 2008:4(2) 401
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pain. (Bajwa et al 2001) Generally, urinary tract infections 
(UTI) are seen in about 60%–70% of adult women and 20% 
of men with ADPKD (Milutinovic et al 1984, 1990; Sklar 
et al 1987). The most frequent clinical presentation is cys-
titis, which is treated in the same manner as in the general 
population. Infected renal cysts may result in symptoms of 
pyelonephritis. Fever and or ﬂ  ank pain are common ﬁ  ndings 
in both pyelonephritis and cyst infection. However, with cyst 
infection, a low-grade fever in association with localized 
ﬂ  ank pain is a common pattern. The pain does not radiate 
and is not relieved by positioning (Bajwa et al 2001). Unlike 
pyelonephritis, urinalysis and cultures may be negative with 
cyst infection, whereas blood cultures are positive in most 
of the cases (Sklar et al 1987). Although infected cysts may 
be difﬁ  cult to diagnose, contrast enhanced CT or MRI and 
scintigraphy with indium-111 labeling of leukocytes are the 
best imaging methods (Bretan et al 1988; Chapman et al 
1990). Since highly ionized, water-soluble antibiotics like 
penicillins and cephalosporins do not readily penetrate the 
renal cyst cavities, they are not effective in ADPKD. Treat-
ment of infected ADPKD cysts should consist of lipophilic 
agents such as clindamycin, ciproﬂ  oxacin, norﬂ  oxacin, and 
trimethoprim- sulfamethoxazole. In most cases therapy 
should continued for 6 weeks. (Bennett et al 1985) In resis-
tant cases, cyst drainage may be needed (Chapman et al 
1990). Inadequate treatment of UTI in ADPKD may lead to 
perinephric abscess with consistent pain and more serious 
complications needing surgical interventions (Sweet and 
Keane 1979).
The prevalence of nephrolithiasis in ADPKD adult 
patients ranges from 20% to 36% (Torres et al 1988; 
Gambaro et al 2006). Twenty to 28% of these patients are 
symptomatic (Milutinovic et al 1990; dimitraovand Sime-
onov 1994), thus a substantial portion of these ADPKD 
patients with nephrolithiasis may be asymptomatic (Levine 
and Grantham 1992). Flank pain, hematuria and UTI are pre-
sentations of nephrolithiasis in ADPKD. The most common 
renal stones in ADPKD are uric acid stones (50%), which is 
a much higher incidence compared to the general population 
(Levine and Grantham 1992; Daudon et al 2003). The low 
prevalence of stones containing calcium, such as calcium 
oxalate, suggests a minor role of hypercalciuria and hyp-
eroxaluria (Torres et al 1993). Stone formation in ADPKD 
patients mostly relates to metabolic defects, and/or urinary 
stasis within structural abnormalities due to cyst compres-
sion. Hypocitraturia has been found to be the most important 
metabolic factor, occurring in approximately 60% and 49% 
of ADPKD patients with and without stones respectively 
(Torres et al 1993; Grampsas et al 2000). In the same study 
Grampsas et al (2000) have reported that the stone-forming 
ADPKD patients have higher cyst numbers and also larger 
cysts compared to non-stone formers. These ﬁ  ndings support 
the theory that cyst enlargement with secondary distortion of 
the renal collecting system contributes to stone formation, 
probably through the mechanism of urine stasis (Torres et al 
1993). Because of the nature of the stone-related urinary 
tract obstruction and distension, pain is a very common 
symptom. Short-term administration of non-steroidal anti-
inﬂ  ammatory drugs (NSAIDs) (limited to two to three days) 
in ADPKD patients suffering from renal colic can be helpful 
(Hetherington and Philp 1986; Osterlinck et al 1990; McIn-
tire et al 1993). These agents may decrease the inﬂ  ammation 
and edema, and thereby facilitate stone passage. Although 
opioids are still a basic analgesic for renal colic therapy, a 
large number of studies have demonstrated no differences 
between the usage of NSAIDs and opioids in the treatment 
of renal calculi. It has been shown that extracorporeal shock 
wave lithotripsy (ESWL) and nephrolithotomy may provide 
favorable results in symptomatic ADPKD patients with renal 
calculi (Anderson et al 1993; Chen et al 1993; Torres et al 
1993; Delakas et al 1997).
Renal cyst rupture in ADPKD may present with acute 
colicky pain, usually associated with gross hematuria 
(Dalgaard 1957). Approximately 42% to greater than 50% 
of ADPKD patients have experienced at least one episode 
of gross hematuria (Rovitch et al 1976; Gabow, Duley and 
Johnson 1992). In 20% of ADPKD patients gross hematu-
ria was the initial diagnostic clue. UTI is the most frequent 
cause of gross hematuria, especially among women. Sports, 
abdominal surgeries, kidney stones and cyst ruptures also 
should be considered as causative factors for gross hematuria 
in ADPKD (Gabow et al 1992). The mean age of the ﬁ  rst 
episode of gross hematuria in ADPKD is approximately 30 
years (Gabow et al 1992). It should be noted that earlier onset 
of bleeding (ie, younger than 30 years), and more frequent 
episodes may indicate a risk of worsening renal function 
(Johnson and Gabow 1997). The incidence of gross hematuria 
is related to both kidney size and hypertension (Gabow et al 
1992). Usually these episodes are self-limited, lasting for 2–7 
days, and are best treated with conservative management. 
However, in cases of prolonged bleeding accompanied by 
pain, renal complications including UTI and/or obstruction 
must be excluded (Gabow et al 1992). Pain associated with 
cyst rupture tends to be more localized. Compression of renal 
structures due to massive hemorrhage may cause radiating 
pain to shoulder or abdomen (Bajwa et al 2001). In severe Therapeutics and Clinical Risk Management 2008:4(2) 402
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cases of gross hematuria prolonged bed rest, hydration and 
analgesic administration are often needed. Usage of NSAIDs 
should be limited. Rarely is hematuria so serious and per-
sistent as to necessitate either nephrectomy or renal arterial 
embolization. Embolization may cause a severe pain, thus 
a combination of pharmalogical agents (eg, NSAIDs and 
opioids), surgical interventions, or an epidural anesthesia 
may be needed (Ordan et al 1983).
Chronic pain
During the prolonged course of the ADPKD, cyst forma-
tion and progressive kidney enlargement may cause a dull, 
chronic pain. Larger renal volumes accompanied by asym-
metric, hypertrophic lumbosacral muscle groups tend to be 
the source of mechanical back pain. Moreover, traction of the 
renal capsule, related to enlarging cysts, is another cause for 
chronic pain in ADPKD patients. As expected, severe chronic 
pain correlates with larger kidneys (Milutinovic et al 1990; 
Bajwa et al 2001). A sequential, approach to chronic pain 
should be employed. A complete, non-judgmental history 
taking is the ﬁ  rst important step. The optional treatments 
consist of:
1.  Physical therapy measures (heating pads, ice massage);
2. Psychobehavioral  modiﬁ  cation techniques;
3. Systemic  analgesics;
4.  Physical interventions such as:
  a.  transcutaneous electrical nerve stimulation (TENS),
  b.  autonomic plexus blockade,
  c.  neuromodulation by spinal cord stimulation,
  d.  neuraxial opioids and local anesthetics,
  e.  surgical decompression of kidney and liver cysts, and
  f.  hepatectomy (partial) and/or nephrectomy.
(Bajwa et al 2001, 2004). Initially the least toxic systemic 
analgesics, eg acetaminophen, should be administered. The 
recommended dose of acetaminophen in patients with renal 
disease is 500–650 mg orally every six hours. It can be 
increased to 1000 mg every four and six hours (Henrich et al 
1996). Surgical or laparoscopic derooﬁ  ng is a conventional 
procedure as an alternative pain management in the case of 
kidneys with several large cysts (Elashry et al 1996; Barr et al 
1998). Sulikowski et al found pain relief after laparoscopic 
renal decortication in 80% of ADPKD patients after 1 year 
and 60% after 3 years (Sulikowski et al 2006). Recently a 
pilot study on 15 selected patients with ADPKD using 99% 
ethanol to decompress renal cysts, showed successful results 
regarding patient’s pain and disappearance of dominant large 
cysts (Singh and Mehrotra 2006). In spite of the small group 
of patients, this procedure should be considered as a safe, 
cost effective therapeutic option in patients suffering from 
chronic ﬂ  ank pain.
Liver cysts
Hepatic cysts are the most frequent extra-renal manifesta-
tions of ADPKD. The prevalence of liver cysts is between 
75 to 90% among ADPKD patients (Milutinovic et al 1980; 
Runfeld et al 1985; Gabow, Johnson et al 1990; D’Agata et al 
1994; Que et al 1995). Age is an independent factor on the 
prevalence of hepatic cysts. In addition to age, deterioration 
of renal function and gender also are risk factors for liver 
disease in patients with ADPKD. The occurrence of hepatic 
cysts in female patients range from 58%–75% while among 
male subjects the prevalence is from 42 to 62%. It is believed 
that estrogen has a stimulatory effect on liver parenchyma and 
increases hepatic cyst volumes without a signiﬁ  cant effect 
on renal volume. Findings of the largest size and number of 
hepatic cysts in multiparous women and postmenopausal 
female patients receiving hormone replacement therapy 
support this hypothesis (Gabow et al 1990; Sulikowski 
et al 2006). Patients with more severe renal disease and 
lower creatinine clearance may present with more liver cyst 
involvement (Gabow, Johnson et al 1990). It is of interest 
that polycystic liver disease may also occur in the absence 
of polycystic kidney disease (Que et al 1995).
Hepatomegaly is the common feature of hepatic 
complications in ADPKD. Most patients often remain 
asymptomatic; however, abdominal mass, pain, early satiety, 
nausea, and vomiting may occur as complications of long-
standing ADPKD liver disease. It should be noted that liver 
functional tests are usually normal in ADPKD patients 
with liver involvement. In symptomatic patients, however, 
alkaline phosphatase and Gamma-glutamyl transferase 
(GGT) values may be elevated in 30%–47% and 60%–70%, 
respectively (Que et al 1995; Sherstha et al 1997). Despite 
the progressive nature of the cystic disease, the hepatic 
parenchyma retains its normal pattern and function (Everson 
et al 1988). Abdominal ultrasound and computer-assisted 
tomography (CT) are recommended methods for radiologic 
evaluations (Levine et al 1985; Everson et al 1988).
Acute hepatic complications are cyst infection and cyst 
hemorrhage. Right abdominal pain accompanied with fever 
in ADPKD patients could be result either from right kidney or 
liver cyst infection (Telenti et al 1990). Infected cysts account 
for 3% of morbidity and 2% of mortality in ADPKD patients 
(Grunfeld et al 1985). The incidence of bacteremia is high 
with infected liver cysts and is detected in about 63% of cases 
with positive blood cultures. The causative agents are usually Therapeutics and Clinical Risk Management 2008:4(2) 403
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Gram-negative organisms such as E.coli (Grunfeld et al 1985; 
Kwok and McDougall 1996), and infected liver cysts should 
be diagnosed and treated aggressively. In order to identify the 
microorganisms, blood and/or cyst ﬂ  uid cultures should be 
employed. In contrast to renal cyst infections, both antibiotic 
therapy and percutaneous cyst drainage under ultrasound or 
CT guidance should be considered in infected liver cysts. 
The antibiotics administered should be capable of penetration 
into liver cysts, such as ciproﬂ  oxacin or amikacin. Additional 
studies are necessary to evaluate newer treatment methods 
including hepatic artery infusion of antibiotics (Matoba 
et al 2004). Cyst hemorrhage may mimic the symptoms of 
an infected liver. This is a rare complication, which can be 
diagnosed best by MRI.
Massively enlarged liver cysts may displace adjacent 
organs, including the gut, diaphragm, and abdominal 
wall, and are responsible for early satiety, abdominal 
hernias, uterine prolapse and dyspnea. Pain is the most 
disabling complication of chronic hepatic disease. Jaundice 
related to biliary compression by cysts has been reported. 
Portal hypertension may occur secondary to portal vein 
compression, but this is uncommon among ADPKD patients 
with liver cysts. Both jaundice and portal vein compression 
may need surgical decompression of cysts (Howard et al 
1976; Simonetti et al 1993; Dmitrewski et al 1996; Misra 
et al 1999). Ascites and variceal bleeding are uncommon 
in the ADPKD patient with liver cysts, but when present 
investigation to rule out vascular thrombosis is indicated 
(Chauveau et al 1997). Huge liver cysts may obstruct hepatic 
venous outﬂ  ow and cause the Budd-Chiari syndrome (Torres 
et al 1994). Several cases have been reported following 
bilateral nephrectomy in ADPKD patients (Torres et al 1994; 
Dioniso et al 1995; Dionisio et al 1997). Sclerotherapy with 
alcohol, resection or fenestration of the hepatic cyst wall may 
be helpful with hepatic venous occlusion caused by solitary 
enlarged cysts. In a study on 35 patients with hepatic cysts, 
the recurrence rate with these treatments after a 1-year follow 
up was 17% (Simonetti et al 1993; van Sonnenberg et al 
1994). Cyst aspiration and sclerosants to treat multiple cysts 
results in more failures with higher symptomatic recurrence 
risk (Simonetti et al 1993; van Sonnenberg et al 1994). In 
these subjects stenting procedures may reestablish hepatic 
venous patency and abolish the pressure gradient. Generally, 
however, liver transplantation must be considered (Yang et al 
2004). As mentioned above, pain in ADPKD patients with 
liver cysts can become both physically and psychologically 
incapacitating. In most cases pharmacological agents are 
ineffective. In the presence of extreme disabling symptoms 
such as malnutrition and/or intolerable pain, surgical 
approaches should be employed (Bajwa et al 2001). Cyst 
fenestration and combined liver resection-fenestration 
are two different surgical strategies. Both laparatomy and 
laparoscopic fenestration have been performed. These 
techniques are more beneficial in superficial and large 
cysts. Because of adverse effects and particularly the higher 
incidence of recurrent symptoms with the cyst fenestration 
technique, combined resection-fenestration seems to be the 
best method to reduce/relieve pain in ADPKD patents with 
cystic liver involvement (Newman et al 1990; Kabbej et al 
1996; Yang et al 2004).
Intracranial aneurysms
Intracranial aneurysms (ICAs) and rupture of intracranial 
aneurysms (RICAs) are critical extra-renal manifestations of 
ADPKD. In the general population the estimated prevalence 
of ICAs derived from autopsy studies is 1%–5%. In contrast 
ICAs are seen in approximately 4%–11.7% of ADPKD 
patients (Chapman et al 1992, 1997; Rinkel et al 1998; The 
International Study of Unruptured Intracranial Aneurysms 
Investigators 1998; Wiebers et al 2003). More than 90% of 
these aneurysms are less than 10 mm and over 70% less than 
6 mm in diameter (Schievink 1997; The International Study 
of Unruptured Intracranial Aneurysms Investigators 1998). 
Familial clustering of aneurysms has been reported both 
in the general population and in ADPKD patients (Hutson 
et al 1993; Schievink 1997; Belz et al 2001). In the general 
population, the incidence of subarachnoid hemorrhage 
(SAH) resulting from a ruptured ICA is about 0.05% per 
year (Schievink 1997; Wijdicks et al 2005). The risk of 
SAH is approximately ﬁ  vefold higher in ADPKD patients 
(Chievink et al 1992). It has been proven that previous 
SAH and size are of the most important factors determining 
the occurrence of an aneurysm rupture (The International 
Study of Unruptured Intracranial Aneurysms Investigators 
1998; Brennan and Schwartz 2000; Juvela et al 2000). The 
International Study of Unruptured Intracranial Aneurysms 
(ISUIA) that included 1449 asymptomatic UIA patients has 
described that the risk of rupture in patients without a prior 
SAH is higher in the cases with aneurysms larger than 
10 mm. Also, it has shown that patients with a history of 
bleeding aneurysm were 10 times more at risk of hemorrhage 
(The International Study of Unruptured Intracranial 
Aneurysms Investigators 1998). The peak incidence of 
SAH in the general population is between 55 and 60 
years (Greenberg 2000). Aneurysmal bleeding in ADPKD 
patients tends to occur at a younger age with a mean age of Therapeutics and Clinical Risk Management 2008:4(2) 404
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35–45 years (Chauveau et al 1994; Chapman et al 1993). RICAs 
are responsible for approximately 80% of SAH’s. It has been 
shown that the mortality rate within 30 days after bleeding 
is almost 45% (Johnston et al 1998). A high proportion 
of individuals surviving a SAH may experience serious 
disabilities. 4%–7% of deaths in patients with ADPKD are 
due to RICAs (Chapman et al 1997). An important concern 
in ADPKD patients with prior RICA is the recurrence of 
SAH. One study showed that 25% of ADPKD patients with 
a previous ICA developed a new ICA over a mean period of 
11.4 years (Belz et al 2003). The increased frequency of ICA 
in ADPKD and the potential life-threatening complications 
has led to the screening of patients. A recent prospective 
10-year follow-up study, conducted at the University 
of Colorado Health Sciences Center, demonstrated that 
among patients with ADPKD who had a previous negative 
imaging study, only a very small percentage (2.6%) had 
a new ﬁ  nding after a mean of 9.8 year follow-up (Schrier 
et al 2004). These ﬁ  ndings have been veriﬁ  ed by another 
study on patients with small-unruptured ICAs ( 7 mm 
in diameter) detected by presymptomatic screening. The 
risk of growth and development of new aneurysms in these 
patients who underwent an imaging follow-up within 81 
months and clinical follow-up of 92 months were low (Gibbs 
et al 2004). Therefore, which patients should be screened, 
remains controversial. Screening in the following sub group 
of patients is highly recommended: patients with positive 
family history of aneurysm or patients with a previous SAH, 
patients with high-risk occupations eg, pilots, patients with 
elective up-coming surgeries that might place the aneurysms 
at a higher risk of rupture and those who request screening. 
As mentioned above, SAH occurs earlier in ADPKD patients, 
thus the screening program for this group should start at a 
young age. Twenty years of age has been recommended for 
screening in high-risk patients (Chauvau et al 1994; Hughes 
and Becker 2003). Severe headache is the most prominent 
clinical presentation of ICAs. Many patients describe the 
headache as the “worst headache of their life” (Wijdicks 
et al 2005).
CT angiography (CTA) after a venous injection of a 
contrast agent, magnetic resonance angiography (MRA), 
and angiography by direct intra-arterial catheterization 
(catheter angiography) are the preferred imaging techniques 
for screening ICAs. Non-invasive procedures (CTA and 
MRA) are recommended as the ﬁ  rst approach. Sensitivity 
and speciﬁ  city is considerably higher in MRA rather than CT 
(sensitivity, 0.69–0.99; speciﬁ  city, 1.00) (White et al 2001; 
Kouskours et al 2004).
The optimal management of intact or ruptured aneurysms 
has not been well understood. In general, observation, 
craniotomy with clipping, or endovascular occlusions with 
the use of detachable coils (coiling) are treatment strategies. 
It has been shown that orally administered nimodipine 
(60 mg every four hours for 21 days) after SAH will improve 
the outcomes (Barker and Ogilvy 1996). Incidentally 
discovered small aneurysms ( 10 mm) need not to be 
treated. Close observation and regular periodic surveillances 
are necessary in these subjects. Although previously it was 
believed that clipping compared to coiling resulted in a 
lower recurrence rate (David et al 1999), recent studies 
have demonstrated that the use of coils tend to have a lower 
inpatient mortality rate, shorter hospital stay, and lower costs 
(Johnston et al 1999, 2000, 2001).
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